Home > Haematology > EHA 2019 > Myeloid Malignancies > Guadecitabine vs treatment of choice in AML

Guadecitabine vs treatment of choice in AML

Presented By
Prof. Pierre Fenaux, Hôpital Saint-Louis, France
Conference
EHA 2019
Trial
Phase 3, ASTRAL-1
The phase 3 ASTRAL-1 study compared the use of guadecitabine to treatment of choice (ToC) in patients with acute myeloid leukaemia (AML) who had not received prior treatment and who were not eligible for intensive chemotherapy. This study failed to meet the primary endpoint of a statistical difference in complete response (CR) and overall survival (OS) between guadecitabine and ToC. However, Prof. Pierre Fenaux (Hôpital Saint-Louis, France) presented data that a benefit was observed in patients who received >4 cycles, indicating that treatment duration is crucial to response. Around 40% of patients in both arms did not receive the minimum of 4 cycles to see the maximum treatment benefit [1]. Guadecitabine is a next-generation hypomethylating agent designed to be resistant to degradation by cytidine deaminase and prolong t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on